Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study on the Safety and Effectiveness of Rilpivirine Hydrochloride (Edurant) Among Adult Filipino Patients With Human Immunodeficiency Virus Type-I Infection

This study has been withdrawn prior to enrollment.
(The company decided to cancel this study in conformity with Philippines FDA Circular 2013-004)
Information provided by (Responsible Party):
Janssen Pharmaceutica Identifier:
First received: September 21, 2012
Last updated: November 30, 2015
Last verified: November 2015
No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: December 2015
  Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)